Prelude Therapeutics Incorporated (PRLD)
- Previous Close
4.1800 - Open
4.1600 - Bid 2.6000 x 200
- Ask 4.4000 x 200
- Day's Range
3.4200 - 4.1800 - 52 Week Range
1.6600 - 6.8900 - Volume
112,395 - Avg. Volume
69,400 - Market Cap (intraday)
188.927M - Beta (5Y Monthly) 1.50
- PE Ratio (TTM)
-- - EPS (TTM)
-2.0200 - Earnings Date May 6, 2024 - May 10, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
5.80
Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.
preludetx.comRecent News: PRLD
Performance Overview: PRLD
Trailing total returns as of 4/18/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: PRLD
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: PRLD
Valuation Measures
Market Cap
188.93M
Enterprise Value
-27.12M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.80
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
0.21
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-33.19%
Return on Equity (ttm)
-56.33%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-121.83M
Diluted EPS (ttm)
-2.0200
Balance Sheet and Cash Flow
Total Cash (mrq)
232.94M
Total Debt/Equity (mrq)
7.12%
Levered Free Cash Flow (ttm)
-58.93M